Neutral
Eli Lilly's stock drops 4.64% amid market volatility on October 8, 2026.
Eli Lilly's stock declined by 4.64% on October 8, 2026, amid broader market fluctuations. The company continues to make significant strides in its pipeline, including advancements in its obesity and oncology treatments. However, concerns about valuation and potential pricing pressures on key drugs like Mounjaro and Zepbound persist.
Key points
- Eli Lilly's stock fell 4.64% on October 8, 2026, amid market volatility.
- The company is expanding its oncology portfolio, with the FDA granting orphan-drug designation to olomorasib for pancreatic cancer.
- Lilly's oral GLP-1 candidate, Foundayo, shows promising data, indicating potential for weight loss and improved blood sugar control.
- Analysts maintain a 'Moderate Buy' consensus on Lilly's stock, with an average price target of $1,311.96, suggesting potential upside.
Sources
- Eli Lilly, Glaukos among market cap stock movers on ThursdayInvesting.com · October 8, 2026
- Eli Lilly and Company (NYSE:LLY) Stock Jumps 1.3% - What's Next?MarketBeat · October 6, 2026
- Eli Lilly and Company (NYSE:LLY) Stock Jumps 1.3% - What's Next?MarketBeat · October 6, 2026
- Eli Lilly and Company (NYSE:LLY) Stock Jumps 1.3% - What's Next?MarketBeat · October 6, 2026
AI-generated from public news sources. Not financial advice.
